Events & Presentations

Date	Event Details
Feb 5, 2020 4:30 PM EST	Arrowhead Pharmaceuticals 2020 First Quarter Results Listen to webcast
Dec 10, 2019 6:00 PM HST	HEP DART 2019 Supporting Materials: View Presentation 6.4 MB View Additional Information Bruce Given, M.D., Arrowhead’s chief operating officer and head of R&D, will deliver an oral presentation titled, “Where will RNAi fit in the era of finite therapies”
Dec 3, 2019 11:00 AM EST	Piper Jaffray 31st Annual Healthcare Conference View Additional Information Fireside chat cancelled Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation with Edward Tenthoff, managing director and senior research analyst at Piper Jaffray
Nov 25, 2019 4:30 PM EST	Arrowhead Pharmaceuticals 2019 Year End Results Listen to webcast Supporting Materials: Prepared Remarks 191.4 KB
Nov 18, 2019	American Heart Association Scientific Sessions 2019 Supporting Materials: RNA Interference Targeting Hepatic Angiopoietin-Like Protein 3 Results in Prolonged Reductions in Plasma Triglycerides and LDL-C in Human Subjects 867.9 KB RNA Interference Targeting Apolipoprotein C-III Results in Deep and Prolonged Reductions in Plasma Triglycerides 493.1 KB Location: Philadelphia View Additional Information November 18, 9:32 a.m. EST – Dr. Christie Ballantyne, Baylor Coll Med, Houston, TX, will deliver an oral presentation titled, “RNA Interference Targeting Apolipoprotein C-III Results in Deep and Prolonged Reductions in Plasma Triglycerides” November 18, 9:38 a.m. EST – Dr. Gerald Watts, Univ of Western Australia, Royal Perth Hosp, Perth, Australia, will deliver an oral presentation titled, “RNA Interference Targeting Hepatic Angiopoietin-Like Protein 3 Results in Prolonged Reductions in Plasma Triglycerides and LDL-C in Human Subjects”
Nov 8 - Nov 12, 2019	The Liver Meeting® 2019, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD) Supporting Materials: Dose Response with the RNA Interference Therapy JNJ-3989 Combined with Nucleos(t)ide Analogue Treatment in Expanded Cohorts of Patients with Chronic Hepatitis B 226.2 KB First Clinical Experience with RNA Interference-based Triple Combination Therapy in Chronic Hepatitis B: JNJ-3989, JNJ-6379 and a Nucleos(t)ide Analogue 199.1 KB Location: Boston View Additional Information Dose Response with the RNA Interference Therapy JNJ-3989 Combined with Nucleos(t)ide Analogue Treatment in Expanded Cohorts of Patients with Chronic Hepatitis B Publication Number: 0696 Session: Hepatitis B - Therapeutics: New Agents Session Date and Time: November 8, 2019 from 8:00 AM to 5:30 PM EST Location: Hynes Convention Center, Hall B Authors: Edward Gane, et al. FIRST CLINICAL EXPERIENCE WITH RNA INTERFERENCE [RNAi]-BASED TRIPLE COMBINATION THERAPY IN CHRONIC HEPATITIS B (CHB): JNJ-73763989 (JNJ-3989), JNJ-56136379 (JNJ-6379) AND A NUCLEOS(T)IDE ANALOGUE (NA) Publication Number: LP4 Session: Late-Breaking Poster Session Session Date and Time: November 11, 2019 from 8:00 AM to 5:30 PM EST Location: Hynes Convention Center, Hall B Authors: Man-Fung Yuen, et al.
Oct 31, 2019 11:15 AM CDT	North American Cystic Fibrosis Conference Supporting Materials: View Presentation 1.6 MB Location: Nashville View Additional Information Erik Bush, Ph.D., Arrowhead’s vice president of extra-hepatic targeting, will deliver a poster presentation titled, “Therapeutic Inhibition of ENaC With a Lung-Targeted RNAi Molecule Delivery Platform Preserves Normal Mucus Clearance in a Mucostatic Sheep Model of Cystic Fibrosis”
Oct 28, 2019 2:30 PM EDT	DIA/FDA Oligonucleotide-Based Therapeutics Conference Supporting Materials: View Presentation 2.5 MB Location: North Bethesda, MD View Additional Information James Hamilton, M.D., Arrowhead’s vice president of clinical development, will deliver an oral presentation titled, “The emerging safety and activity of siRNA drugs using the TRIMTM platform”
Oct 18, 2019 8:00 AM EDT	Arrowhead Analyst R&D Day 2019 Listen to webcast Supporting Materials: View Presentation 40.1 MB Location: New York, NY
Oct 7, 2019 1:30 PM EDT	Chardan 3rd Annual Genetic Medicines Conference Listen to webcast Location: New York, NY View Additional Information Bruce Given, M.D., Arrowhead’s chief operating officer and head of R&D, will participate in a fireside chat presentation with Keay Nakae, CFA, Chardan senior research analyst